endpts.com·Jun 26, 2026
Biogen has decided to pause or cancel most of the research programs acquired from its $5.6 billion purchase of Apellis Pharmaceuticals, resulting in significant layoffs.
Biogen's decision to pause or cancel the majority of research programs following its $5.6 billion acquisition of Apellis Pharmaceuticals underscores a strategic shift towards prioritizing high-potential assets. For someone tracking healthtech and biotech investment opportunities, this move highlights the importance of closely evaluating post-acquisition strategies of biotech companies, as it may signal potential redirection of resources towards more promising areas that could impact future market dynamics and investment opportunities.